Both President Trump’s and President Biden’s administrations have emphasized in executive orders and presidential memoranda the need for objective, science-based decision-making. However, Trump’s May 23, 2025, Executive Order...more
5/29/2025
/ Biden Administration ,
Diversity and Inclusion Standards (D&I) ,
Executive Orders ,
Government Agencies ,
OSTP ,
R&D ,
Regulatory Reform ,
Regulatory Requirements ,
Research and Development ,
Scientific Research ,
Transparency ,
Trump Administration
President Trump’s highly publicized executive order 14297, titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” targets the discrepancy in drug pricing in the United States compared with...more
5/16/2025
/ Antitrust Provisions ,
Department of Health and Human Services (HHS) ,
Direct to Consumer Sales ,
Drug Pricing ,
Executive Orders ,
Food and Drug Administration (FDA) ,
Healthcare ,
International Trade ,
Most-Favored Nations ,
Patient Access ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Requirements ,
Trump Administration ,
U.S. Commerce Department
President Trump’s May 5, 2025, executive order titled “Regulatory Relief to Promote Domestic Production of Critical Medicines” sets out the administration’s goals to increase the domestic manufacture of critical...more
5/8/2025
/ Country of Origin ,
Drug Pricing ,
Environmental Policies ,
Environmental Protection Agency (EPA) ,
Executive Orders ,
Food and Drug Administration (FDA) ,
Healthcare ,
Life Sciences ,
Manufacturers ,
Manufacturing Facilities ,
Patient Access ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Reform ,
Supply Chain ,
Trump Administration